Editas Medicine downgraded to Underweight from Neutral at JPMorgan

JPMorgan downgraded Editas Medicine (EDIT) to Underweight from Neutral wirthout a price target The company last week announced the decision to pivot its research and development to focus on in vivo pipeline, the analyst tells investors in a research note. The firm believes there is “significant value” embedded in Editas’ technical expertise and intellectual property estate, but believes the “next major inflection point in the stock is still ways away.”